Yang et al. [184] demonstrated successful tumor in vitro and in vivo targeting using folate ligand, which is the ligand for FR, and the formulation which included the co-delivery of DOX and Bmi1 siRNA by folate-DOX/Bmi1 siRNA liposome effectively prevented tumor growth (Table 1). This evidence concerns the gene BMI1 and neoplasm.